374 reports of this reaction
5.0% of all BACITRACIN ZINC reports
#1 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #1 most commonly reported adverse reaction for BACITRACIN ZINC, manufactured by Topco Associates LLC. There are 374 FDA adverse event reports linking BACITRACIN ZINC to DRUG HYPERSENSITIVITY. This represents approximately 5.0% of all 7,550 adverse event reports for this drug.
Patients taking BACITRACIN ZINC who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among BACITRACIN ZINC users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for BACITRACIN ZINC:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 374 FDA reports for BACITRACIN ZINC. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 5.0% of all adverse event reports for BACITRACIN ZINC, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking BACITRACIN ZINC, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.